TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02448459
Drug: COOL-COS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled ovarian stimulation will start on the second or third day of a menstrual cycle: Oral clomiphene citrate: 100 mg/day until the day of the triggering. Oral letrozole: 7.5 mg/day during the first 5 days of the controlled ovarian stimulation.~Corifollitropin Alfa: 100 mcg on the 3rd day of the controlled ovarian stimulation.~The triggering will be performed using leuprorelin 1 mg (subcutaneous).
Study: NCT01525589
Drug: PM01183
Approvals — FDA: no, EMA: no, PMDA: no
Description: PM01183 drug product (DP) is presented as a lyophilized powder for concentrate for solution for infusion with two strengths: 1 mg/vial and 4 mg/vial
Study: NCT00751374
Drug: gentamicin
Normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: topical gentamicin cream on daily basis
Study: NCT00751374
Drug: gentamicin cream alternating with mupirocin cream
Normalized name: mupirocin Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical gentamicin cream alternating with mupirocin cream at monthly basis
Study: NCT02167464
Drug: Renin treatment-guided Therapeutics
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients are treated based upon their renin levels according to an approved algorithm.
Study: NCT01701921
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill designed to mimic pregabalin capsule, by mouth one hour before surgery
Study: NCT00686036
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03831633
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: * oral aprepitant 125mg (Day 1) and 80mg daily (on Day 2 and Day 3)~* IV ondansetron 8 mg on Day 1~* Dexamethasone 12 mg on Day 1 and 8 mg daily from Day 2 to Day 4
Study: NCT00751166
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo once daily for 28 days
Study: NCT01031706
Drug: Hypertonic Saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: inhaled HS (6% NaCl, 4mL) three times a day for 28 days
Study: NCT01031706
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ml 0.12% NaCl inhaled three times a day x 28 days
Study: NCT01185288
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate capsule
Study: NCT01505465
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5mg of melatonin will be taken by the subject for 3 nights prior and continuing 3 nights after surgery as tolerated.
Study: NCT01505465
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mg of placebo will be taken by the subject 3 nights prior to surgery and continuing 3 nights after surgery
Study: NCT00679783
Drug: AZD2281
Approvals — FDA: no, EMA: no, PMDA: no
Description: PARP inhibitor Olaparib tablets, oral
Study: NCT01364077
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo
Study: NCT03009500
Drug: Depo-Medrol Injectable Product
Normalized name: DEPO-Medrol Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00437320
Drug: Metvix Cream 160 mg/g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants were treated with topical administration of Metvix cream.
Study: NCT00437320
Drug: Metvix Vehicle Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants were treated with topical administration of Metvix Vehicle cream.
Study: NCT02876302
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg/m2, IV (in the vein) every 14 days for 4 doses.
Study: NCT02876302
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 mg/m2, IV (in the vein) every 14 days for 4 doses.
Study: NCT03860233
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal spray to mimic Oxytocin intranasal spray
Study: NCT04318678
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide is a nitrogen mustard derivative. It acts as an alkylating agent that causes cross-linking of DNA strands by binding with nucleic acids and other intracellular structures, thus interfering with the normal function of DNA.
Study: NCT00878670
Drug: EPOGAM 1000
Normalized name: Epogam
Approvals — FDA: no, EMA: no, PMDA: no
Description: One capsule of EPOGAM 1000 contains 932-1073 mg Oenothera seminis oleum, equivalent to 80 mg gamma-linolic acid. Children (2-12 years) take 2 capsules in the morning and evening, whereas persons over 12 years take 3 capsules in the morning and evening. The duration of the treatment is 12 weeks.
Study: NCT00901368
Drug: FOSTER
Normalized name: Foster and Thrive Biotin
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHF1535 (beclometasone dipropionate 100 µg plus formoterol 6 µg) pMDI aerosol via HFA-134a propellant 2 inhalations b.i.d. (daily dose 400 µg + 24µg)
Study: NCT01457820
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo, stat dose, then 5 days of matched placebo BD.
Study: NCT03928158
Drug: LCZ 696
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50-100-200 mg tablet
Study: NCT03949842
Drug: Inhaled corticosteroids/long-acting beta2-adrenergic/long-acting muscarinic receptor antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: A fixed dose of combination ICS/LABA plus LAMA once-daily was administered to COPD subjects using two separate non-ELLIPTA devices.
Study: NCT00762671
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1 po BID for 2 weeks
Study: NCT01845142
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03441269
Drug: Oral Ibuprofen
Normalized name: ibuprofen Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Ibuprofen will be given to all the arms; only the dosage will be different: 400mg vs. 600mg vs. 800mg
Study: NCT03971123
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to AC-SD-03 50g of AC-SD-03P mixed in 240mL dosing liquid at Hour 0 Day 1
Study: NCT02848170
Drug: CS-3150
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS-3150 2.5mg, oral
Study: NCT01224964
Drug: long acting beta2 mimetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICS+long acting beta2 agonist: twice daily
Study: NCT01975961
Drug: Crestor 20mg(Rosuvastatin 20mg), Micardis 80mg(Telmisartan 80mg) , FDC
Approvals — FDA: no, EMA: no, PMDA: no
Description: For co-administration, Crestor 1 tablet and Micardis 1 tablet. For FDC administration, FDC 1 tablet.
Study: NCT02633501
Drug: P03277
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous (IV) bolus injection at a rate of 2 mL/second
Study: NCT02093689
Drug: Part 2 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drug product is a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL of solution containing 20 mM sodium citrate buffer (pH 6.3 ± 0.5). For administration to patients, 4.0 mL of the drug product is added to a 500-mL bottle of commercially available irrigation solution.
Study: NCT04479657
Drug: QingFei Granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: QingFei Granule is made from 6 commonly herbal medicine granule, such as Jingjie,Huang Qin,Lianqiao,etc. The children were given one package of QingFei Granule every day, dividing into 3 times to be administrated. It's be given for 5 days.
Study: NCT03131999
Drug: Placebo - Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirolimus or everolimus will be withdrawn after 28 days if used at baseline
Study: NCT01898910
Drug: Optimal medial therapy (OMT)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic and antihypertensive therapy will be administered according to the guidelines
Study: NCT02149875
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml saline intravenous infusion once daily for 10 days.
Study: NCT01032174
Drug: Azithromycin SR
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin SR, 2.0 g by mouth (PO) x 1
Study: NCT01032174
Drug: Amoxiclav 1000 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxiclav 1000 mg x twice daily, 10 days
Study: NCT00166465
Drug: ALIMTA plus Oxaliplatin versus Oxaliplatin plus 5-Fluorouracil and Leucovorin (FOLFOX 4 Regimen)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04499248
Drug: AGN-193408 SR
Normalized name: VITEX AGNUS-CASTUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: An implant containing preservative-free AGN-193408 dispersed in a biodegradable polymer matrix. Implants are preloaded into an applicator to facilitate insertion of the implant into the anterior chamber of the study eye.
Study: NCT04499248
Drug: AGN-193408 SR
Normalized name: VITEX AGNUS-CASTUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: An implant containing preservative-free AGN-193408 dispersed in a biodegradable polymer matrix. Implants are preloaded into an applicator to facilitate insertion of the implant in the study eye.
Study: NCT03624244
Drug: Aromatase Inhibitors
Normalized name: Aromatase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance of AI versus interruption of AI
Study: NCT03943173
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given standard chemotherapy
Study: NCT00131235
Drug: Sulfadoxine-pyrimethamine every 4 weeks + azithromycin twice
Normalized name: Fansidar 500/25 (sulfadoxine / pyrimethamine) Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfadoxine-pyrimethamine, 3 tablets (each containing 500mg of sulfadoxine and 25mg of pyrimethamine), taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and then at 4 week intervals until 37.0 gestation weeks.~2 azithromycin tablets (each 500 mg) taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and another time between 28.0 and 33.9 gestation weeks.
Study: NCT04043520
Drug: Placebo estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patches will be worn by those randomized to the placebo arms in both premenopausal and postmenopausal groups. Patches will be applied weekly and will be worn for the for entirety of the intervention (12 or 24 weeks).
Study: NCT04043520
Drug: Placebo GnRH antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postmenopausal women randomized to the placebo injection arm will receive two placebo drug injections of normal saline (24-week intervention)
Study: NCT00239395
Drug: Meloxicam ampoule
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00239395
Drug: Meloxicam tablet
Normalized name: Meloxicam Tablets
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03961464
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose
Study: NCT01922050
Drug: LEO 43204 Formulation 1
Normalized name: Leo-K
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01922050
Drug: LEO 43204 Formulation 2
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01922050
Drug: LEO 43204 Formulation 1 Dose Y
Normalized name: Y
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01922050
Drug: LEO 43204 Formulation 2 Dose XX
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02805972
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 ml
Study: NCT03099356
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 100 mg, PO, days 1-5 and 15-19
Study: NCT02322528
Drug: Administration of Lotemax
Approvals — FDA: no, EMA: no, PMDA: no
Description: An FDA approved drug (Lotemax) will be administered to induce an inflammatory mediated response in both eyes.
Study: NCT00496509
Drug: ZD6474 (Zactima) 100mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00496509
Drug: ZD6474 (Zactima) 300mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02127047
Drug: Exercise
Normalized name: Tenscare ITouch Sure Pelvic Floor Exerciser
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03496870
Drug: Carbidopa Levodopa
Normalized name: carbidopa / levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa: dopamine precursor Carbidopa: DOPA decarboxylase inhibitor
Study: NCT03211871
Drug: Normal Saline Flush, 0.9% Injectable Solution_#1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative intravenous normal saline infusion
Study: NCT02345226
Drug: FTC/RPV/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200/25/25 mg FDC tablets administered orally once daily
Study: NCT02345226
Drug: EFV/FTC/TDF Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally once daily
Study: NCT02345226
Drug: EFV/FTC/TDF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600/200/300 mg FDC tablets administered orally once daily
Study: NCT01133821
Drug: IPSRT plus placebo (IPSRT-PLA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be seen approximately weekly/biweekly during the 20 week acute phase. All subjects will return at weeks 36 and 52 for follow-up assessments to evaluate the enduring effects of treatment.~The therapist will administer IPSRT and the psychiatrist will administer medication management procedures (quetiapine or placebo).~Medication Dosing~The research pharmacy will dispense medication in the following unit-dose packs:~Dose A (50 mg of QUE or PLA) Dose B (100 mg of QUE or PLA) Dose C (separate packs of 50 mg and 100 mg QUE capsules or PLA) Dose D (200 mg of QUE or PLA) Dose E (separate packs of 50 mg and 200 mg QUE capsules or PLA) Dose F (separate packs of 100mg and 200mg QUE capsules or PLA)
Study: NCT02345226
Drug: FTC/RPV/TAF Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally once daily
Study: NCT03239600
Drug: GSK2618960 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2618960 solution for injection, 100mg/mL is clear to opalescent, colorless to yellow or pale brown liquid.
Study: NCT03239600
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution will be administered by IV infusion.
Study: NCT03239600
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MTX dose between 7.5 to 15 mg will be administered in tablet form once in a week till last dose of GSK2618960 to all subjects in Part I and Part II.
Study: NCT04356742
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin Placebo, orally, once daily, up to 24weeks
Study: NCT03784625
Drug: [131I]ICF01012 (therapeutic dose level 1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: * 1 diagnostic injection (D0) at a diagnostic dose of 185 MBq. This first dose permits to pre-select patients who will received a therapeutic dose according to the dosimetry results ( binding on at least a tumoral lesion, an acceptable radiation absorbed dose to major organs)~* 1 therapeutic injection (D11) at a dose of 800 MBq/m²
Study: NCT03784625
Drug: [131I]ICF01012 (therapeutic dose level 2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: * 1 diagnostic injection (D0) at a diagnostic dose of 185 MBq. This first dose permits to pre-select patients who will received a therapeutic dose according to the dosimetry results ( binding on at least a tumoral lesion, an acceptable radiation absorbed dose to major organs)~* 1 therapeutic injection (D11) at a dose of 1600 MBq/m²
Study: NCT01387282
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets identical in appearance to active tablets; oral administration QD for 12 weeks, at least 1 hour prior to meal before the first meal of the day.
Study: NCT03784625
Drug: [131I]ICF01012 (therapeutic dose level 3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: * 1 diagnostic injection (D0) at a diagnostic dose of 185 MBq. This first dose permits to pre-select patients who will received a therapeutic dose according to the dosimetry results ( binding on at least a tumoral lesion, and an acceptable radiation absorbed dose to major organs)~* 1 therapeutic injection (D11) at a dose of 2700 MBq/m²
Study: NCT03784625
Drug: [131I]ICF01012 (therapeutic dose level 4)
Approvals — FDA: no, EMA: no, PMDA: no
Description: * 1 diagnostic injection (D0) at a diagnostic dose of 185 MBq. This first dose permits to pre-select patients who will received a therapeutic dose according to the dosimetry results ( binding on at least a tumoral lesion, and an acceptable radiation absorbed dose to major organs)~* 1 therapeutic injection (D11) at a dose of 4000 MBq/m²
Study: NCT01368003
Drug: STA9090
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/m\^2 IV every week for 3 weeks on, 1 week off (days 1,8,15 on a 28-day cycle)
Study: NCT03086278
Drug: AST-008
Approvals — FDA: no, EMA: no, PMDA: no
Description: AST-008 is a toll-like receptor 9 agonist.
Study: NCT03265470
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive Loading dose of fentanyl (1μg/kg), followed by intravenous infusion (1μg/kg/h) during intra-operative period till end of procedure.
Study: NCT01321060
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Including antibiotics,somatostatin, proton pump inhibitors and sufficient fluid resuscitation
Study: NCT02744703
Drug: total-etch adhesive
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: comparator use of total-etch adhesive
Study: NCT02744703
Drug: self-etch adhesive
Approvals — FDA: no, EMA: no, PMDA: no
Description: comparator use of total-etch adhesive
Study: NCT00788073
Drug: STX209
Approvals — FDA: no, EMA: no, PMDA: no
Description: Variable dose from 1 mg bid to 10 mg tid, Capsule, Oral, 4 weeks
Study: NCT00788073
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: variable dose (same flexible dose titration protocol), bid to tid, capsule, Oral, 4 weeks
Study: NCT03491267
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No drug will be given
Study: NCT02661126
Drug: MK-3682B
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC oral tablet containing 225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir.
Study: NCT03755167
Drug: IPL344
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPL344 will be administered by intravenously (IV) infusion once a day (every 24±6 hours), using a Peripherally Inserted Central Catheter (PICC) line or a permanent port. IPL344 will be administered using an electronic pump at a flow rate that will be determined in protocol 101/2. The dose will be fixed as MTD as established in protocol 101/2 (up to 3.2 mg/kg).
Study: NCT02611518
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin will be administered as a single oral 10 milligram (mg) dose on Day 1 and Day 14.
Study: NCT01921426
Drug: GC4419
Approvals — FDA: no, EMA: no, PMDA: no
Description: GC4419 is a novel, highly stable manganese-containing macrocyclic ligand complex with a molecular weight of 483, whose activity mimics that of naturally occurring superoxide dismutase (SOD) enzymes. It is therefore a prototype of a new class of drugs termed selective SOD mimetics. GC4419 selectively removes superoxide anions without reacting with other reactive oxygen species, including nitric oxide, hydrogen peroxide, and peroxynitrite.
Study: NCT00353158
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100mg twice daily for 3 days. Two hours after the last dose of doxycycline is taken in the clinic, on-medication phototesting with ssUVR, UVA, and visible light will be performed.
Study: NCT01923987
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Oxaliplatin 85 mg/m2 IV over 2 hrs on Day 1~* Irinotecan 180 mg/m2 IV over 30-90 mins on Day 1~* Leucovorin 400 mg/m2 IV over 2 hrs on Day 1 and 2~* 5-fluorouracil bolus 400 mg/m2 IV push on Day 1 and 2 (or 5-fluorouracil infusion 600 mg/m2 IV continuous infusion over 22 hrs).~* Bevacizumab 5 mg/kg IV over 90 mins on Day 1~* Cetuximab (only for patients with K-ras wild type and positive EGFR mutation) 400 mg/m2 IV over 2 hrs on Day 1, and 250 mg/m2 IV over 1 hr on Day 8, 15, 22, 29, and 36.~* FOLFOX or FOLFIRI (+-Bevacizumab ) repeats every 14 days for up to 3 courses. Cetuximab repeats every week for up to 6 courses~* Postoperative FOLFOX or FOLFIRI (+-Bevacizumab or Cetuximab) for up to 9 cycles (total 12 cycles)
Study: NCT03890185
Drug: Chemo alone
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemo alone: Intervention will include chemotherapy using Docetaxel 75mg/m2 IV D1 and Cisplatin (CDDP) 75mg/m2 IV D1 given for 2 cycles every 21 days.
Study: NCT01268020
Drug: [18F]-FMH3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be injected with up to 5 mCi and not to exceed 5.5mCi (not \>10% of 5 mCi limit) or 2 ug of \[18F\]-FMH3, whichever is greatest.
Study: NCT03588156
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02127593
Drug: Norgestimate /Ethinyl estradiol tablets (NGM/EE) (Wet Process)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norgestimate /Ethinyl estradiol tablets (NGM/EE) containing norgestimate 250 mcg and ethinyl estradiol 35 mcg, formulated by wet process will be orally administered on Day 1 of Period 1 or Period 2.
Study: NCT02127593
Drug: Norgestimate /Ethinyl estradiol tablets (NGM/EE) (Dry Process)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norgestimate /Ethinyl estradiol tablets (NGM/EE) containing norgestimate 250 mcg and ethinyl estradiol 35 mcg, formulated by dry process will be orally administered on Day 1 of Period 1 or Period 2.
Study: NCT01869881
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 100mg 2 tablets, bid, 400mg/day
Study: NCT01667692
Drug: azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin (Zithromax, Azithrocin ) is an azalide, a subclass of macrolide antibiotics. Azithromycin is one of the world's best-selling antibiotics.\[1\] It is derived from erythromycin, with a methyl-substituted nitrogen atom incorporated into the lactone ring, thus making the lactone ring 15-membered.